Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - November 2025

Cencora executive Heather Zenk discusses how innovations in cold chain, data visibility, and sustainability strategies are transforming the drug delivery process.

Building Resilient, Sustainable Pharma Supply Chains

From patent cliffs and government price controls, to self-pay models and staff-model HMOs, a look at the forces that could deflate the bubble—and those factors likely to keep it afloat a while longer.

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

Advice for pharma distributors and dispensers on what they should do now in order to solidify a secure supply chain.

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead

Articles

How pharma manufacturers can steadily navigate GTN components and                                             complexities when planning pharmacy benefit reimbursement.

Popping the Gross-to-Net Bubble, Part III: The Pharmacy Benefit

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

Steffen Lang, president, operations, executive committee member, Novartis, shares strategic insights on how pharma supply chain leaders can elevate operations to drive innovation, growth, and patient impact.

LogiPharma Europe 2025: The Evolving Role of Operations in Advancing Therapeutic Delivery

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, details the aspect of her presentation that she would have wanted to dive further into.

Hubs East 2025: Pushing Back Against Cost-Shifting Programs

The latest news for pharma industry insiders.

Pharma Pulse 4/10/25: Treating Chronic Cough with Digital Therapeutics, ADHD Stimulants Have Minimal Effect on Cardiovascular System & more

How can stakeholders prepare for changing therapy requirements?  

LogiPharma Europe 2025: Reevaluating One’s CGT Value Chain

Respective industry and government agendas could significantly reshape the US prescription drug market.

US Drug Price Negotiations and Transparency

SVP of Customer Distribution Experience at McKesson. She leads the company’s distribution strategy across the US for brand, generic, and specialty pharmaceuticals.

Ensuring that essential treatments reach patients safely and efficiently is an increasing imperative in today's pharma landscape.

Strategies to Modernize, Future-Proof, and Secure the Healthcare Supply Chain

A keynote presentation describes how supply chain visibility should rely on digital capabilities. 

LogiPharma Europe 2025: Being a Part of an AI-Powered E2E Supply Chain

Steffen Lang, president, operations, executive committee member, Novartis, discusses the premise of a keynote session on reimagining operations. 

LogiPharma Europe 2025: Reimagining Operations to Deliver the Future of Personalized Medicine

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, shares his thoughts on the rumors that RFK Jr. could potentially ban DTC advertising.

Featured Content

Pharmaceutical Commerce - November 2025

Building Resilient, Sustainable Pharma Supply Chains

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead